MBRX — Moleculin Biotech, Inc.

Is MBRX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Moleculin Biotech, Inc. (MBRX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.61. The rating moved from Neutral to Oversold on August 11, 2026.

See all oversold Healthcare stocks →

AI analysis

Moleculin Biotech, Inc. is a small-cap, clinical-stage biotech whose value is concentrated in a limited set of development programs and upcoming milestones. The company exhibits typical pre-revenue characteristics—high cash burn, financing dependence, and binary clinical/regulatory event risk—while benefiting only indirectly from broader sector tailwinds in biologics and CDMO demand. Near-term share movement is likely to be driven by trial updates, partnership activity, and funding events. Downside risks include clinical failure, dilution from capital raises, regulatory delays, and limited liquidity, any of which could produce sharp share-price declines. Upside scenarios require positive clinical data or strategic partnerships that materially de-risk programs and improve financing options.

Key factors

  • Clinical-stage profile with value tied to a small number of trial readouts and regulatory milestones
  • Limited or no sustained product revenue, implying reliance on financing and partnerships for runway
  • High market volatility and low float typical of micro-cap biotech names, amplifying price moves on news
  • Sector-level tailwinds for biologics and CDMO demand that may indirectly benefit development or partnering prospects
  • Potential for near-term catalysts (trial updates, partnership or licensing announcements) that could move the stock materially

Risks

  • Clinical or regulatory setbacks for lead programs that could materially reduce valuation
  • Cash runway constraints and likelihood of dilutive capital raises that depress shares
  • Commercial uncertainty including payer coverage and pricing if programs advance
  • Competition from larger biotech/pharma with greater resources and overlapping therapeutic approaches
  • Low liquidity increasing downside risk on negative headlines and reducing ability for orderly exits
  • Macro risk: broader biotech risk-off or rising rates could compress speculative small-cap valuations

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for MBRX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.